ADMP Stock Summary and Trading Ideas (Adamis Pharmaceuticals | NASDAQ:ADMP)

Adamis Pharmaceuticals Corp is a specialty biopharmaceutical company focused on developing and commercializing products in various therapeutic areas, including allergy, opioid overdose, respiratory and inflammatory disease. Its products and product candidates in the allergy, respiratory, and opioid overdose markets include SYMJEPI (epinephrine) Injection 0.3mg and Injection 0.15mg for use in the emergency treatment of acute allergic reactions, including anaphylaxis; a naloxone injection product candidate, ZIMHI, based on the approved Symject injection device and intended for the treatment of opioid overdose; Tempol, an investigational drug; and a Beclomethasone metered dose inhaler product candidate (APC-400) intended for the treatment of Covid-19.

Adamis Pharmaceuticals trades on the NASDAQ stock market under the symbol ADMP.

As of March 31, 2023, ADMP stock price was flat at $0.12 with 431,872 million shares trading.

ADMP has a beta of 0.83, meaning it tends to be less sensitive to market movements. ADMP has a correlation of 0.03 to the broad based SPY ETF.

ADMP has a market cap of $19.98 million. This is considered a Sub-Micro Cap stock.

In the last 3 years, ADMP stock traded as high as $2.34 and as low as $.10.

The top ETF exchange traded funds that ADMP belongs to (by Net Assets): VTI, VXF, ITOT.

ADMP has underperformed the market in the last year with a price return of -79.4% while the SPY ETF lost -9.8%. ADMP has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -29.1% and -0.7%, respectively, while the SPY returned +6.9% and +3.6%, respectively.

ADMP support price is $.11 and resistance is $.13 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ADMP stock will trade within this expected range on the day.